الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 132 |  |  |
| | | from | 132 | | |
Abstract
Brucella is one of the world’s main zoonotic pathogens, in Egypt; it is as high as 8% in high risk populations. The symptoms are fever, fatigue, malaise, chills, sweating, headaches, myalgia, arthralgia and weight loss.
The combination therapies recommended by the (WHO) in the treatment of adult human brucellosis were (Rifampicin plus Doxycycline) for 45 days. The most effective and the least toxic chemotherapy for human brucellosis are still undetermined.
The aim of this present study is to evaluate the efficacy, adverse effects and cost of (Ofloxacin plus Rifampicin) therapy for 30 days versus (Doxycycline plus Rifampicin) therapy for 45 days in the treatment of adult human brucellosis. This study was carried out in Maghagha Fever Hospital in the period from (the 1st of August 2012 to the 1st of August 2013).
The diagnosis was based on presence of symptoms and clinical signs compatible with positive SAT titers with or without positive blood culture. Patients were divided into two equal groups. Group 1 was treated with (Rifampicin 600mg/day) plus (Doxycycline 200mg/day) for 45 days while group 2 with (Rifampicin 600mg/day) plus (Ofloxacin 400mg/day) for 30 days.
Clinically, no significant difference was found between the two groups. Fever dropped more rapid in group 2. Post end of therapy one relapse was seen in each group. Although duration of therapy was two weeks shorter in group 2, the cure rate was the same in both groups.
Because of the similar efficacy, adverse effects and nearly the cost between the two regimens, (Ofloxacin plus Rifampicin) therapy for 30 days is recommended to be used as a new regimen in the treatment of adult human brucellosis.